For Patients

If you would like to use the patient decision aid, please contact your neurologist.

We are still conducting pilot testing of the decision aid - if you would like to participate, please contact us here. More information about the study can be found below.

RMS-PtDA pilot study

Study: A Patient Decision Aid for Relapsing Multiple Sclerosis Treatments (RMS-PtDA)

Principal Investigator: Dr. Robert Carruthers

Co-Principal Investigator: Dr. Anthony Traboulsee


    • The purpose of this tool is to improve outcomes of care for patients. We hope it will better inform individuals so they can have better conversations about difficult treatment choices with their neurologist and health care team.

Inclusion criteria

You may qualify as a participant if you meet the following criteria:

    • Have a clinical diagnosis of relapsing-remitting multiple sclerosis (RRMS)
    • Are 18 years of age or older
    • Have not previously used a disease modifying therapy, or are considering changing from a first line therapy to another first line therapy
    • Have internet access
    • Read and understand English

What does the study involve?

Over 6 to 7 months, you will be asked to complete 4 surveys, the educational tool (the RMS-PtDA), and participate in a structured follow-up interview. All information collected from your surveys is anonymous.

    • Month 0:
        • Provide consent to participate in study
        • Schedule a follow-up visit/call with your neurologist/health care team
        • Complete surveys/RMS-PtDA online (45 minutes)
            • Complete baseline survey
            • Use the RMS-PtDA
            • Complete post-intervention survey
    • Month 1 to 3:
        • Discuss the results of the RMS-PtDA with my neurologist in person or on the phone
        • Complete post-consultation survey online (10 minutes)
    • Month 6:
        • Complete a 6-month follow-up survey online (10 minutes)
    • Month 6 to 7:
        • Follow-up interview on the phone (20 minutes)

What are the risks and benefits?

There are no known risks for participating in this study.

You will benefit by being potentially better informed about the treatment options available to you and being able to engage in more meaningful conversations with your doctors before making treatment decisions.


If you are interested in participating, please contact us here.